News

It represents a compound annual growth rate (CAGR) of 8.4%. The report said that the UK’s life sciences sector features just under 5000 firms that develop, manufacture and

The JV, Avvinity Therapeutics, will be based in the UK. It has been launched to create a platform to discover and develop immuno-oncology therapeutics for solid tumours and

Rexall Health employs over 8,600 people in over 470 pharmacies throughout Canada. The company also operates Rexall Specialty Pharmacy, a division which offers clinical care and complex medication

A study by the University of Southampton recruited over 1,000 pregnant women who took either 1000 units of vitamin D every day or a matched placebo capsule from

The ARRIVE Study is a randomized, double-blinded, allocation-concealed, placebo-controlled, proof-of-concept Phase IIa clinical trial, which is an investigator-initiated study, and is being conducted at the NAFLD Research Center,

Preparations are underway to begin a pivotal Phase 3 clinical trial of AeroVanc, the first inhaled antibiotic being developed to address the growing problem of methicillin-resistant Staphylococcus aureus

The FDA will review Xolair in children from six through 11 years for the treatment of moderate to severe persistent asthma in those patients with a positive skin

Approximately 7.5 million people in the U.S. are diagnosed with some form of psoriasis, a chronic immune-mediated skin disorder presenting with varying symptoms and levels of severity. Based

Emtricitabine and tenofovir alafenamide are from Gilead Sciences, while rilpivirine is from Janssen Sciences Ireland UC. Odefsey is Gilead’s second TAF-based regimen to secure FDA approval and represents